ScreenerHero

CBIO Crescent Biopharma, Inc.

NAS · US · Healthcare · Biotechnology · crescentbiopharma.com
13.57USD-2.65%Mkt Cap: 504.08M $P/E: —

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VE…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INSM
Insmed Incorporated
$22.98BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap504.08M USD
Enterprise Value414.65M USD
Revenue (TTM)11.88M USD
Gross Profit11.88M USD
Net Income (TTM)-153.94M USD
Revenue/Share0.43 USD
Last Price13.57 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.16
PEG—
EV/EBITDA-2.44
EV/Revenue34.89
P/S42.42
P/B2.85
EPS (TTM)-7.63
EPS (Forward)-2.63
52W Range
8.72026% of range27.41
52W High27.41 USD
52W Low8.720 USD
Profitability
Gross Margin100.00%
Oper. Margin-1432.63%
EBITDA Margin0.00%
Profit Margin-1419.61%
ROE-75.83%
ROA-64.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-71.53M USD
CapEx (TTM)72.92M USD
FCF Margin—
FCF Yield—
Net Debt-170.16M USD
Net Debt/EBITDA1.00
Balance Sheet
Debt/Equity0.01
Current Ratio9.66
Quick Ratio9.26
Book Value/Sh4.77 USD
Cash/Share4.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJun 16, 2025
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)31.50 USD
Upside (mean)+132.1%
Target Range27.00 USD – 36.00 USD
27.00+132.1% to mean36.00
# Analysts6
Ownership
Shares Out.37.14M
Float27.03M
Insiders0.27%
Institutions82.90%
Short Interest
Short Ratio12.3d
Short % Float15.74%
Short % Out.9.17%
Shares Short3.41M
Short (prev mo.)3.22M
Technical
SMA 5016.78 (-19.1%)
SMA 20015.74 (-13.8%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)443.94K
Avg Vol (10d)381.90K
Technical Indicators
RSI (14)31.6
MACD-1.0369
MACD Signal-0.7290
MACD Hist.-0.3080
BB Upper21.81 USD
BB Middle16.53 USD
BB Lower11.26 USD
BB Width63.79%
ATR (14)1.196 USD
Vol Ratio (20d)0.94x